Kyverna Therapeutics, Inc.
KYTX
$1.81
-$0.02-1.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 112.47M | 96.15M | 77.37M | 59.60M | 45.84M |
| Gross Profit | -112.47M | -96.15M | -77.37M | -59.60M | -45.84M |
| SG&A Expenses | 30.13M | 23.99M | 19.01M | 15.71M | 12.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.60M | 120.14M | 96.37M | 75.31M | 58.50M |
| Operating Income | -142.60M | -120.14M | -96.37M | -75.31M | -58.50M |
| Income Before Tax | -127.48M | -110.66M | -89.25M | -72.57M | -57.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.48 | -110.66 | -89.25 | -72.57 | -57.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.48M | -110.66M | -89.25M | -72.57M | -57.02M |
| EBIT | -142.60M | -120.14M | -96.37M | -75.31M | -58.50M |
| EBITDA | -141.42M | -119.05M | -98.37M | -65.23M | -48.45M |
| EPS Basic | -3.46 | -28.53 | -48.59 | -68.12 | -79.10 |
| Normalized Basic EPS | -2.15 | -17.78 | -30.34 | -42.55 | -49.43 |
| EPS Diluted | -3.46 | -28.53 | -48.59 | -68.12 | -79.10 |
| Normalized Diluted EPS | -2.15 | -17.78 | -30.34 | -42.55 | -49.43 |
| Average Basic Shares Outstanding | 153.27M | 110.83M | 68.30M | 25.78M | 2.95M |
| Average Diluted Shares Outstanding | 153.27M | 110.83M | 68.30M | 25.78M | 2.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |